Measurement of Parathyroid Hormone

Dynamics of Bone and Cartilage Metabolism

Volumn , Issue , 2006, Pages 507-512

  Jüppner, Harald ^a   Fuleihan, Ghada El Hajj ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36248935123     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088562-6/50031-5     Document Type: Chapter

References (53)

1. Jüppner H., Gardella T., Brown E., Kronenberg H., Potts J. Parathyroid hormone and parathyroid hormone-related peptide in the regulation of calcium homeostasis and bone development. Endocrinology 2000, 969-998. W.B. Saunders Company, Philadelphia, PA. L. DeGroot, J. Jameson (Eds.).
2. Murray T.M., Rao L.G., Divieti P., Bringhurst F.R. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocr Rev 2005, 26:78-113.
3. D'Amour P., Brossard J., Rousseau L., Nguyen-Yamamoto L., Nassif E., Lazure C., Gauthier D., Lavigne J., Zahradnik R. Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int. 2005, 68:998-1007.
4. Inomata N., Akiyama M., Kubota N., Jüppner H. Characterization of a novel PTH-receptor with specificity for the carboxyl-terminal region of PTH(1-84). Endocrinology 1995, 136:4732-4740.
5. Usdin T.B., Gruber C., Bonner T.I. Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J. Biol. Chem. 1995, 270:15455-15458.
6. Usdin T.B., Wang T., Hoare S.R.J., Mezey E., Palkovits M. New members of the parathyroid hormone/parathyroid hormone receptor family: the parathyroid hormone 2 receptor and tuberin-fundibular peptide of 39 residues. Frontiers in Neuroendocrinology 2000, 21:349-383.
7. Slatopolsky E., Finch J., Clay P., Martin D., Sicard G., Singer G., Gao P., Cantor T., Dusso A. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000, 58:753-761.
8. Nguyen-Yamamoto L., Rousseau L., Brossard J.H., Lepage R., D'Amour P. Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 2001, 142:1386-1392.
9. Divieti P., Inomata N., Chapin K., Singh R., Jüppner H., Bringhurst F. Receptors for the carboxyl-terminal region of PTH(1-84) are highly expressed in osteocytic cells. Endocrinology 2001, 142:916-925.
10. Divieti P., John M., Jüppner H., Bringhurst F. Human PTH-(7-84) inhibits bone resorption in vitro viaactions independent of the type I PTH/PTHrP receptor. Endocrinology 2002, 143:171-176.
11. Demay M., Mitchell J., Goltzman D. Comparison of renal and osseous binding of parathyroid hormone and hormonal fragments. Am. J. Physiol. 1985, 249:E437-E446.
12. McKee M.D., Murray T.M. Binding of intact parathyroid hormone to chicken renal membranes: evidence for a second binding site with carboxyl-terminal specificity. Endocrinology 1985, 117:1930-1939.
13. Murray T.M., Rao L.G., Muzaffar S.A. Dexamethasone-treated ROS 17/2.8 rat osteosarcoma cells are responsive to human carboxylterminal parathyroid hormone peptide hPTH(53-84): stimulation of alkaline phosphatase. Calcif. Tissue Int. 1991, 49:120-123.
14. Rao L.G., Murray T.M. Binding of intact parathyroid hormone to rat osteosarcoma cells: major contribution of binding sites for the carboxyl-terminal region of the hormone. Endocrinology 1985, 117:1632-1638.
15. Langub M., Monier-Faugere M., Wang G., Williams J., Koszewski N., Malluche H. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 2003, 144:1135-1138.
16. Brossard J.H., Clouthier M., Roy L., Lepage R., Gascon-Barre M., D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J. Clin. Endocrinol. Metab. 1996, 81:3923-3929.
17. Lepage R., Roy L., Brossard J.H., Rousseau L., Dorais C., Lazure C., D'Amour P. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem. 1998, 44:805-809.
18. Brossard J., Lepage R., Cardinal H., Roy L., Rousseau L., Dorais C., D'Amour P. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin. Chem. 2000, 46:697-703.
19. D'Amour P., Brossard J.H., Rakel A., Rousseau L., Albert C., Cantor T. Evidence that the amino-terminal composition of non-(1-84) parathyroid hormone fragments starts before position 19. Clin. Chem. 2005, 51:169-176.
20. Kunii I., Vieira J. Circulating forms of parathyroid hormone detected with an immunofluorometric assay in patients with primary hyperathyroidism and in hyperparathyroidism secondary to chronic renal failure. Braz. J. Med. Biol. Res. 2001, 34:1547-1550.
21. Gao P., Scheibel S., D'Amour P., John M., Rao S., Schmidt-Gayk H., Cantor T. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J. Bone Miner. Res. 2001, 16:605-614.
22. Berson S.A., Yalow R.S., Aurbach G., Potts J.T. Immunassay of bovine and human parathyroid hormone. Proc. Natl. Acad. Sci. USA 1963, 49:613-617.
23. Segre G.V., Potts J.T. Differential Diagnosis of Hypercalcemia. Endocrinology 1995, 1075-1093. W. B. Saunders, Philadelphia. L.J. DeGroot (Ed.).
24. Nussbaum S.R., Zahradnik R.J., Lavigne J.R., Brennan G.L., Nozawa-Ung K., Kim L.Y., Keutmann H.T., Wang C.A., Potts J.T., Segre G.V. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin. Chem. 1987, 33:1364-1367.
25. Jüppner H., Potts J.T. Immunoassays for the detection of parathyroid hormone. J. Bone Miner. Res. 2002, 17(Suppl 2):N81-N86.
26. Goodman W.G., Jüppner H., Salusky I.B., Sherrard D.J. Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Kidney Int. 2003, 63:1-11.
27. Martin K.J., Akhtar I., Gonzalez E.A. Parathyroid hormone: new assays, new receptors. Semin. Nephrol. 2004, 24:3-9.
28. Ekins R. More sensitive immunoassays. Nature 1980, 284:14-15.
29. D'Amour P., Brossard J.H., Rousseau L., Roy L., Gao P., Cantor T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin. Chem. 2003, 49:2037-2044.
30. John M., Goodman W., Gao P., Cantor T., Salusky I., Jüpper H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J. Clin. Endocrinol. Metab. 1999, 84:4287-4290.
31. Salusky I.B., Goodman W.G., Kuizon B.D., Lavigne J.R., Zahranik R.J., Gales B., Wang H.J., Elashoff R.M., Juppner H. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 2003, 63:1801-1808.
32. Hatakeyama Y., Mizunashi K., Furukawa Y., Yabuki S., Sato Y., Igarashi T. Plasma levels of parathyroid hormone (1-84) whole molecule and parathyroid hormone (7-84)-like fragments in pseudohypoparathyroidism type I. J. Clin. Endocrinol. Metab. 2003, 88:2250-2255.
33. Savoca R., Bock A., Kraenzlin M.E., Schmid H.R., Huber A.R. An automated 'bio-intact' PTH assay: a step towards standardisation and improved correlation with parathyroid function in renal disease. Clin. Chim. Acta 2004, 343:167-171.
34. Silverberg S.J., Gao P., Brown I., LoGerfo P., Cantor T.L., Bilezikian J.P. Clinicalutility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2003, 88:4725-4730.
35. Yamashita H., Gao P., Cantor T., Noguchi S., Uchino S., Watanabe S., Ogawa T., Kawamoto H., Fukagawa M. Comparison of parathyroid hormone levels from the intact and whole parathyroid hormone assays after parathyroidectomy for primary and secondary hyperparathyroidism. Surgery 2004, 135:149-156.
36. Bouillon R., Coopmans W., Degroote D., Radoux D., Eliard P. Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. Clin. Chem. 1990, 36:271-276.
37. Fournier A., Solal M., Oprisiu R., Mazouz H., Morinire P., Choukroun G., Bouillon R. Optimal range of plasma concentration of true 1-84 parathyroid hormone of patients on maintenance dialysis. J. Clin. Endocrinol. Metab. 2001, 86:1840-1842.
38. Carnevale V., Dionisi S., Nofroni I., Romagnoli E., Paglia F., De Geronimo S., Pepe J., Clemente G., Tonnarini G., Minisola S. Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin. Chem. 2004, 50:626-631.
39. Silverberg S., Bilezikian J. "Incipient" primary hyperparathyroidism: a "forme fruste" of an olddisease. J. Clin. Endocrinol. Metab. 2003, 88:5348-5352.
40. Monier-Faugere M., Geng Z., Mawad H., Friedler R., Gao P., Cantor T., Malluche H. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001, 60:1460-1468.
41. Kazama J.J., Omori T., Ei I., Ei K., Oda M., Maruyama H., Narita I., Gejyo F., Shigematsu T., Fukagawa M. Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia. Clin. Exp. Nephrol. 2003, 7:144-149.
42. Coen G., Bonucci E., Ballanti P., Balducci A., Calabria S., Nicolai G., Fischer M., Lifrieri F., Manni M., Morosetti M., Moscaritolo E., Sardella D. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am. J. Kidney Dis. 2002, 40:348-354.
43. Inaba M., Okuno S., Imanishi Y., Ueda M., Yamakawa T., Ishimura E., Nishizawa Y. Significance of Bio-intact PTH(1-84) assay in hemodialysis patients. Osteoporos Int. 2004, 16:517-525.
44. Sherrard D., Hercz G., Pei Y., Maloney N., Greenwood C., Manuel A., Saiphoo C., Fenton S., Segre G. The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int. 1993, 43:436-442.
45. Salusky I., Coburn J., Brill J., Foley J., Slatopolsky E., Fine R., Goodman W. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int. 1988, 33:975-982.
46. Yamashita H., Cantor T., Uchino S., Watanabe S., Ogawa T., Moriyama T., Takamatsu Y., Fukagawa M., Noguchi S. Sequential changes in plasma intact and whole parathyroid hormone levels during parathyroidectomy for secondary hyperparathyroidism. World J. Surg. 2005, 29:169-173.
47. Weinstein L., Yu S., Warner D., Liu J. Endocrine Manifestations of Stimulatory G Protein alpha-Subunit Mutations and the Role of Genomic Imprinting. Endocr. Rev. 2001, 22:675-705.
48. Jan de Beur S.M., Levine M.A. Pseudo-hypoparathyroidism: Clinical. Biochemical, and Molecular Features. The Parathyroids: Basic and Clinical Concepts 2001, 807-825. Academic Press, New York. J.P. Bilezikian, R. Markus, M.A. Levine (Eds.).
49. Bastepe M., Jüppner H. The GNAS locus and pseudohypoparathyroidism. Hormone Research 2005, 63:65-74.
50. Bastepe M., Fröhlich L., Hendy G., Indridason O., Josse R.H.K., Körkkör J., Nakamoto J., Rosenbloom A., Slyper A., Sugimoto T., Tsatsoulis A., Crawford J., Jüppner H. Autosomal dominant pseudohypoparathyroidism type-1b is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J. Clin. Invest. 2003, 112:1255-1263.
51. Laspa E., Bastepe M., Jüppner H., Tsatsoulis A. Phenotypic and molecular genetic aspects of pseudohypoparathyroidism type Ib in a Greek kindred: evidence for enhanced uric acid excretion due to parathyroid hormone resistance. J. Clin. Endocrinol. Metab. 2004, 89:5942-5947.
52. Mahmud F., Linglart A., Bastepe M., Jüppner H., Lteif A. Molecular diagnosis of pseudohypoparathyroidism type Ib in a family with presumed paroxysmal dyskinesia. Pediatrics 2005, 115:e242-e244.
53. Bastepe M., Fröhlich L., Linglart A., Abu-Zahra H., Tojo K., Ward L., Jüppner H. Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. Nat. Genet. 2005, 37:25-27.